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The mutation cluster region (MCR) of adenomatous polyposis coli (APC) is located within the central part
of the open reading frame, overlapping with the region encoding the 20 amino acid repeats (20R) that are
b-catenin-binding sites. Each mutation in the MCR leads to the synthesis of a truncated APC product
expressed in a colorectal tumour. The MCR extends from the 30 border of the first 20R coding region to
approximately the middle of the third 20R coding region, reflecting both positive and negative selections
of the N- and C-terminal halves of the APC protein in colon cancer cells, respectively. In contrast, the
second 20R escapes selection and can be either included or excluded from the truncated APC products
found in colon cancer cells. To specify the functional outcome of the selection of the mutations, we investi-
gated the b-catenin binding capacity of the first three 20R in N-terminal APC fragments. We found in
co-immunoprecipitation and intracellular co-localization experiments that the second 20R is lacking any
b-catenin binding activity. Similarly, we also show that the tumour-associated truncations abolish the
interaction of b-catenin with the third 20R. Thus, our data provide a functional definition of the MCR: the
APC fragments typical of colon cancer are selected for the presence of a single functional 20R, the first
one, and are therefore equivalent relative to b-catenin binding.
INTRODUCTION
Inactivation of the tumour suppressor adenomatous polyposis
coli (APC) is the earliest known mutagenic event that initiates
tumoral progression towards the development of colon cancer
(1). APC is a crucial component of the so-called b-catenin
destruction complex that catalyses the efficient phosphoryl-
ation of b-catenin, which is subsequently degraded in the pro-
teasome (2). In colon cancer, one consequence of APC
inactivation is the stabilization of b-catenin that in turn
feeds the cell with a permanent mitogenic signal (3,4).
Indeed, a plethora of data has proven that the stabilization of
b-catenin is an essential driving force allowing the hyperpro-
liferation of the epithelial cells of the colon (5–8).
The central region of the 2843 amino acid APC sequence
(9) harbours interaction domains involved in binding and/or
regulation of b-catenin. They include the so-called 15 amino
acid repeats (15R, labelled A–D) (10) and 20 amino acid
repeats (20R, numbered 1–7) that are b-catenin binding
sites and the SAMP repeats that interact with axin/conductin
(11) (Fig. 1). Thus, APC can bring b-catenin in the vicinity
of axin/conductin that in turn recruits casein kinase I and
glycogen synthase kinase 3b. These kinases catalyse the
sequential phosphorylation of b-catenin, which is an essential
prerequisite for proteasomal degradation (12–15).
Both alleles of APC are mutated in the vast majority of
colon tumours (16–21). The mutations are either nonsense
substitutions or frame shifts resulting from small insertions
or deletions that affect the open reading frame. Interestingly,
several mutational hotspots occur within direct repeated
sequences, likely the consequence of replication errors (22).
Allelic loss, which implies deletion of the whole open
reading frame or somatic conversion (23) also contributes to
APC inactivation. As a consequence of these mutational
events, colon cancer cells express only truncated versions of
APC (21).
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In the familial adenomatous polyposis coli (FAP) syndrome,
one mutated APC allele is transmitted through the germ-line
(24). Subsequent somatic mutations inactivate the second
allele and precede the development of many polyps early in
the adulthood that evolve systematically into malignant
tumours. This hereditary disease allowed observing that the
sequence of mutational events affecting both alleles is not a
random process (25–27). If the germ-line defect is either a
loss of heterozygosity or a truncating mutation occurring
before the first 20R, then a truncating mutation will affect
the remaining allele after the first 20R. Thus, there is a
strong selection for the retention of at least one truncated
APC product containing the first 20R. The importance of
this selection has been highlighted in a recent report
showing that truncated APC is required for optimal cell pro-
liferation (28). In addition, there is also an almost systematic
selection for truncating mutations occurring before the first
SAMP repeat. Thus, it is thought that the truncating mutations
are selected to preclude the formation of a functional
destruction complex by eliminating the binding sites for
axin/conductin (29).
The consequence of the double—positive and negative—
selection is that the recorded mutations from FAP patients
accumulate between the first 20R and the first SAMP
repeats, in the so-called mutation cluster region (MCR)
(19–21) (Fig. 1). With only very few exceptions, the 50
border of the MCR is clearly located just after the first 20R
and we have shown recently that it is an important structural
motif allowing truncated APC to keep some residual control
on b-catenin activity (30). The 30 border of the MCR is less
well defined. Although the selected truncated APC isoforms
almost systematically lack the first SAMP repeat, there is an
apparent mutation gap between this motif and position 1494
where a bulk of mutations accumulate, suggesting that
amino acid 1494 represents a critical position beyond which
only few mutations are permissive for tumour development.
Interestingly, the structure of the third 20R in a complex
with b-catenin (31,32) reveals two parts that provide import-
ant contact sites to b-catenin. The C-terminal portion after
position 1494 is characterized by a cluster of serines that dras-
tically enhance the affinity for b-catenin when they are phos-
phorylated. The N-terminal portion contains D1486 and E1494
that are crucial residues directly interacting with K435 and
K312, the two so-called charged buttons in the b-catenin
armadillo repeat. These two lysine residues were also
observed as direct contact points in the very similar structures
of b-catenin complexed with either E-cadherin (33) or Tcf3
(T-cell factor) (34) and their individual mutation into aspartate
has been shown to abolish the interaction of b-catenin with
Tcf3 (34). These data suggested that APC truncations might
be selected for altered b-catenin binding activity to the
third 20R.
Figure 1. Schematic representation of APC and amino acid sequence of the MCR and flanking regions. The axin/conductin binding sites (SAMP) and the 15 and
20R as well as the position of the MCR are indicated above the scheme. Each dot above the sequence is representative of a nonsense or frame-shift somatic mutation
found in a colorectal tumour that led to the synthesis of a truncated APC product. The double bars indicate 10 more mutations. The 20R are underlined and the
interaction interface of the 20R3 with b-catenin (31,32) is boxed. The charged residues that are making crucial contacts with b-catenin are marked with bold
letters. Known phosphorylation sites in the 20R3 are marked with asterisks. Amino acid positions are indicated with arrows. The scheme is modified from (43).
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Similarly, it is striking that the second amino acid repeat is
apparently left outside any selective pressure. Interestingly,
the first negatively charged amino acid residue that is interact-
ing directly with one of the two charged buttons of b-catenin
in the other 20R is exchanged for a lysine at position 1370 in
the second 20R (31,32). In addition, it has been established
recently that among all APC-derived repeats displaying a
b-catenin binding activity, the second 20R had the lowest affi-
nity when they were analysed individually in vitro (35). These
observations suggested that the second 20R might be unable to
bind b-catenin in the context of a truncated APC.
In this study we investigated the ability of truncated APC to
bind to b-catenin. Our data reveal that only the first 20R is
functional for b-catenin binding, whereas the second repeat
and the remaining half of the third repeat up to position
1493 cannot bind to b-catenin. Thus, our data provide a ration-
ale for the absence of selection of the second 20R and for the
abrupt drop of APC mutation frequency after position 1494 in
the middle of the third 20R.
RESULTS
To investigate the ability of the 20R2 (second 20R) to bind to
b-catenin in the context of a truncated APC molecule, we first
compared the activities of YFP(yellow fluorescent
protein)-APC fusions containing (yAPC1404) or lacking
(yAPC1289) the 20R2 (Figs 1 and 2). Co-immunoprecipitation
experiments indicated that both of them were binding to
b-catenin with a very similar efficiency. Thus, the presence
or absence of the 20R2 does not modify b-catenin binding.
As the binding of b-catenin to the 15R and 20R1 (first 20R)
may be too strong to observe the contribution of the 20R2,
we disrupted the b-catenin binding activity of the four 15R
and the 20R1 by exchanging residues crucial for the inter-
action. In the crystallographic structure of b-catenin in a
complex with the first 15R (36), Y1027 and Y1031 of APC
make direct contacts with R386 of b-catenin. Mutation of
the latter residue into alanine drastically affected the associ-
ation with the first 15R (37). Therefore Y1027 and Y1031
were exchanged for alanine or leucine whereas the highly con-
served S1028 for glycine (Fig. 3A). The consequence of these
mutations was investigated in a hybrid protein made of YFP
fused to the first mutated 15R [yAPC(959–1037)15Rm]
whose b-catenin-binding activity was compared with that of
the corresponding wild-type construct [yAPC(959–1037)].
Immunoprecipitation experiments revealed that the three
residue replacements were sufficient to abolish the interaction
of b-catenin with the first 15R (Fig. 3B).
Similarly, to hamper b-catenin binding to the 20R1, we
exploited its property to bind to b-catenin with a high affinity
only when it is phosphorylated (31,32,35,38,39). Therefore,
S1272, S1275, S1276, S1278 and S1281 were mutated into
alanine in the context of an APC sequence extending from
amino acid 2 to 1289 fused to YFP (yAPC1289-20R1m)
(Fig. 3C). The b-catenin binding activity of this construct,
the corresponding wild-type fusion (yAPC1289) and shorter
constructs lacking either 20R1 (yAPC1247) or both all 15R
and the 20R1 (yAPC891) were compared. Immunoprecipita-
tion experiments revealed that among the four fusion proteins
only yAPC1289 was displaying a strong b-catenin binding
activity (Fig. 3D). In contrast, yAPC891 showed no binding
to b-catenin, whereas yAPC1247 and yAPC1289-20R1m
were binding only weakly owing to the presence of the 15R.
Thus, the mutations introduced in the 20R1 were efficient in
abolishing its interaction with b-catenin.
To characterize the b-catenin binding activity of the 20R2,
the mutations described above were introduced in all four 15R
and the 20R1 in the context of a truncated APC extending
from amino acid 2 to 1404 and therefore containing an
intact 20R2 (yAPC1404-15Rm-20R1m) (Fig. 4A). As negative
controls, we used yAPC891 as well as yAPC1289 where all
the four 15R and the 20R1 were mutated (yAPC1289-
15Rm-20R1m). A positive control consisted of yAPC1289
containing four mutated 15R but a wild-type 20R1
(yAPC1289-15Rm). Immunoprecipitation experiments
revealed that yAPC1289-15Rm was binding efficiently to
b-catenin relative to yAPC891 (Fig. 4B). In contrast,
yAPC1289-15Rm-20R1m displayed only a background
activity similar to yAPC891, confirming that the mutations
Figure 2. Deletion of the second 20R (20R2) of APC does not affect the inter-
action with endogenous b-catenin. (A) Schematic representation of YFP-APC
constructs. (B) Transient transfection of HEK293T cells with constructs indi-
cated above the lanes was followed by immunoprecipitation with an anti-GFP
antibody and western blotting using either anti-GFP or anti-b-catenin anti-
body. A densitometry analysis reports the b-catenin/yAPC ratio of the
signals seen on the blots.
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introduced in the repeats were efficiently reducing the
association with b-catenin. Moreover, extending yAPC1289-
15Rm-20R1m with the 20R2 as seen in yAPC1404-
15Rm-20R1m did not restore any b-catenin binding activity,
indicating that the 20R2 cannot interact with b-catenin in
these settings.
To confirm this result, we measured the transcriptional
activity of b-catenin in a reporter assay. As positive controls,
we used expression vectors encoding either a full length
YFP-APC fusion or a shorter version extending up to the
end of the first SAMP repeat (yAPC1641). These two con-
structs efficiently inhibited the transcriptional activity of
b-catenin (Fig. 4C). yAPC1289 and yAPC1404 were also inhi-
biting the transcriptional activity of b-catenin, with a similar
efficiency. This inhibition required binding to b-catenin,
because yAPC1289-15Rm-20R1m was inactive in the assay.
Figure 3. Mutations in the 15 and 20R of APC affect the interaction with endogenous b-catenin. (A) The sequences of the 15R (A–D) are shown together with
their positions in the full length APC molecule. The amino acid residues highlighted in bold were replaced by alanine or glycine in all the four 15R, except by
leucine for the tyrosine at the third position in 15R-B. The YFP-APC fusion proteins used in B are shown schematically. An M-labelled black box represents a
mutated repeat. (B) The effect of the mutations described in A on b-catenin binding is shown for the first 15R only. To test this, transient transfection of SW480
cells with the indicated constructs was followed by immunoprecipitation with an anti-GFP antibody and western blotting using either anti-GFP or anti-b-catenin
antibody. (C) Schematic representation of the YFP-proteins used in D and amino acid sequence of the 20R1. The serines indicated with arrows were replaced by
alanine in the yAPC1289-20R1m construct. An M-labelled black box represents a 20R1 containing the mutations. (D) Transient transfection of HEK293T cells
with the constructs shown in C was followed by immunoprecipitation with an anti-GFP antibody and western blotting using either anti-GFP or anti-b-catenin
antibody. A densitometry analysis reports the b-catenin/yAPC ratio of the signals seen on the blots.
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Addition of the 20R2, as seen in yAPC1404-15Rm-20R1m, did
not restore the inhibiting activity. Thus, this experiment
suggested that the 20R2 does not contribute to the down-
regulation of b-catenin-dependent transcription.
To investigate the ability of 20R2 to associate with
b-catenin inside the cells, we used the property of truncated
APC to build intracellular inclusions (40). We also observed
previously (30) that b-catenin co-localizes in these structures
and we hypothesized that this was dependent on the ability
of APC to interact with b-catenin. Therefore, YFP,
yAPC1289-15Rm, yAPC1289-15Rm-20R1m and yAPC1404-
15Rm-20R1m were transiently expressed in SW480 cells
where endogenous b-catenin can be easily visualized by
immunofluorescence staining (Fig. 4D). In this experiment
YFP localized diffusely in both the nucleus and the cytoplasm,
whereas the three yAPC fusion proteins formed in addition
Figure 4. The second 20R (20R2) of APC does not bind to b-catenin. (A) Schematic representation of YFP-APC constructs. An M-labelled black box represents
a repeat mutated as shown in Figure 3. (B) Transient transfection of HEK293T cells with the indicated YFP-APC fusions constructs and a myc-b-catenin
expression plasmid was followed by immunoprecipitation with an anti-GFP antibody and western blotting using either anti-GFP or anti-b-catenin antibody.
The asterisk indicates an unspecific band. A densitometry analysis reports the b-catenin/yAPC ratio of the signals seen on the blots. (C) SW480 cells were
transiently transfected with either a b-catenin-dependent reporter gene (TOP) or a control reporter gene (FOP) and either an empty vector (flag) or the indicated
expression vectors. Represented is the mean TOP/FOP ratio of three experiments. FOP activities were not significantly altered in the different conditions.
(D) Transient transfection of SW480 cells with the indicated constructs was followed by immunostaining using an anti-b-catenin antibody. Arrowheads indicate
transfected cells.
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cytoplasmic inclusions. b-catenin partially co-localized in
these inclusions when yAPC1289-15Rm was expressed.
In contrast, the b-catenin staining pattern remained diffuse
in the presence of yAPC1289-15Rm-20R1m, thus revealing
the efficiency of the mutations introduced in the four 15R
and the 20R1 in destroying the interaction with b-catenin.
Figure 5. b-Catenin binding to the 20R3 defines the 30 border of the MCR. (A) Schematic representation of YFP-APC constructs. An M-labelled black box
represents a mutated repeat. (B) Transient transfection of HEK293T cells with the indicated YFP-APC fusion constructs and a myc-b-catenin expression
plasmid was followed by immunoprecipitation with an anti-GFP antibody and western blotting using either anti-GFP or anti-b-catenin antibody. The asterisk
indicates an unspecific band. A densitometry analysis reports the b-catenin/yAPC ratio of the signals seen on the blots. (C) RFP-b-catenin recruitment in MCF7
cells and TOP/FOP reporter assays in SW480 cells. Transient transfection of MCF7 cells with the indicated constructs together with an RFP-b-catenin expression
plasmid was followed by immunofluorescence analysis. The numbers indicate the percentage of RFP-b-catenin-positive cells (n ¼ 100) displaying only cyto-
plasmic RFP-b-catenin. Hoechst, DNA staining. TOP/FOP reporters ratios were determined as described in legend of Figure 4C after transfection of yAPC1641
and the indicated constructs in SW480 cells. Inhibition of the TOP/FOP ratio is given relative to the inhibiting activity of yAPC1641, which was set to 100%.
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As the b-catenin staining remained also diffuse in cells
expressing yAPC1404-15Rm-20R1m, we concluded that the
20R2 cannot bind to b-catenin in this experiment.
To investigate the capacity of the 20R3 (third 20R) to inter-
act with b-catenin, the construct yAPC1404-15Rm-20R1m
was extended up to either approximately the middle of the
20R3 at position 1502 (yAPC1502-15Rm-20R1m) or shortly
after at position 1519 (yAPC1519-15Rm-20R1m) (Figs 1 and
5A). Immunoprecipitation experiments confirmed the lack of
interaction between yAPC1404-15Rm-20R1m and b-catenin
(Fig. 5B). yAPC1519-15Rm-20R1m was binding strongly to
b-catenin, but yAPC1502-15Rm-20R1m did not display any
b-catenin binding activity. Thus, residues 1502–1519 rep-
resent an important determinant of the interaction. This is in
line with the role of the serine residues located in this
portion and whose phosphorylation has been shown to drasti-
cally enhance the affinity of the 20R3 for b-catenin
(31,32,38,41).
To visualize the interaction of b-catenin with the 20R3
inside the cells, we employed MCF7 cells in which truncated
APC constructs located in the cytoplasm and depleted the
nucleus from co-expressed RFP(red fluorescent protein)-
b-catenin (Fig. 5C). For this experiment, several constructs
were designed, all of them containing mutated 15R and
20R1 and extending from amino acid 2 to either 1494
(yAPC1494-15Rm-20R1m), 1493 (yAPC1493-15Rm-20R1m)
or 1466 (yAPC1466-15Rm-20R1m) (Fig. 5A). In addition,
we also created yAPC1519-15Rm-20R1m-20R3m as a nega-
tive control where five known phosphorylatable serine resi-
dues in the 20R3 (S1501, S1504, S1505, S1507 and S1510)
(31) were mutated into alanine and where E1494 and D1486
(Fig. 1) that are making direct contacts with b-catenin
(31,32) were also exchanged for alanine residues. E1494 and
D1486 were mutated in addition to the serines to destroy effi-
ciently any residual b-catenin binding activity, because an
unphosphorylated 20R3 displays an affinity for b-catenin in
the same range as a phosphorylated 20R1 in vitro (35).
These constructs, as well as yAPC1519-15Rm-20R1m,
yAPC1502-15Rm-20R1m and YFP were transiently expressed
in MCF7 cells together with a RFP-b-catenin fusion protein.
Immunofluorescence observation showed that YFP and
RFP-b-catenin localized diffusely throughout the cell when
they were co-expressed, mainly in the nucleus (Fig. 5C). All
yAPC constructs were located predominantly, if not exclu-
sively, in the cytoplasm and there was no apparent difference
of fluorescence intensity between them. In the presence of
either yAPC1519-15Rm-20R1m or yAPC1502-15Rm-20R1m,
RFP-b-catenin was absent from the nucleus of 60 and 58%
of RFP-b-catenin-positive cells, respectively. This effect was
concentration-dependent because b-catenin was found in the
nucleus of cells expressing either high amounts of
RFP-b-catenin or low amounts of the yAPC fusions. In con-
trast, RFP-b-catenin was located predominantly in the cyto-
plasm of only 4 and 12% of the cells expressing either
yAPC1519-15Rm-20R1m-20R3m or yAPC1466-15Rm-20R1m.
Thus, as described earlier (42), a retention mechanism pre-
vents b-catenin from reaching the nucleus and this occurs
through binding to the 20R3 because the retention effect is
abolished when the essential features responsible for a high
b-catenin binding affinity are mutated in the 20R3 or when
the entire repeat is deleted. yAPC1494-15Rm-20R1m had the
best retention capacity, since RFP-b-catenin was almost
exclusively cytoplasmic in 80% of positive cells. Remarkably,
shortening yAPC1494-15Rm-20R1m by the removal of a
single amino acid residue (yAPC1493-15Rm-20R1m) resulted
in a drastic impairment of the retention, since RFP-b-catenin
was predominantly cytoplasmic in only 19% of cells expres-
sing yAPC1493-15Rm-20R1m, near the level observed with
yAPC1466-15Rm-20R1m where the entire repeat has been
deleted. A western blotting analysis indicated that differential
expression could not explain these differences (unpublished
data). Thus amino acid 1494 represents a crucial limit below
which b-catenin recruitment is barely detectable. To confirm
this result, the different abilities of the yAPC constructs to
inhibit the transcriptional activity of b-catenin were measured
in the TOP/FOP reporter assay (Fig. 5C). We found a good
correlation between the ability of the constructs to recruit
b-catenin and to inhibit its transcriptional activity, highlight-
ing again the importance of amino acid 1494. Strikingly, a
bulk of natural APC truncating mutations is selected up to pos-
ition 1494 (Fig. 1), after which the frequency of mutations
drops drastically. These observations strongly suggest that
APC mutations are selected for altered b-catenin binding to
the 20R3.
Several natural mutations however occur after the critical
1494 position (Fig. 1). This situation is represented by our
two constructs extending up to positions 1502 or 1519. Inter-
estingly, yAPC1519-15Rm-20R1m and yAPC1502-15Rm-
20R1m display a reduced ability to retain RFP-b-catenin in
the cytoplasm when compared with yAPC1494-15Rm-20R1m
(Fig. 5C). This suggests that b-catenin binding might also be
altered despite the presence of the phosphorylatable residues
in some rare cases. The natural frame-shift mutations occur-
ring in codons 1502 and 1519 result in the addition of six
extra amino acids after position 1502 and the replacement of
D1519 by a glutamate residue, followed by a termination
codon (21). These sequence alterations were incorporated in
our constructs but they had no apparent influence on
RFP-b-catenin recruitment in comparison with yAPC1519-
15Rm-20R1m and yAPC1502-15Rm-20R1m (unpublished
data). Thus, our data suggest that mutations occurring after
position 1494 are exceptions that are selected because of
altered b-catenin binding activity to the 20R3.
DISCUSSION
Almost all APC mutations that are selected in colorectal
tumours lead to the synthesis of truncated APC products that
contain a 20R1 fully competent in b-catenin binding. In con-
trast, the mutations distribute on either sides of the 20R2. To
understand why there is no apparent selective pressure for
the presence or the absence of the 20R2, we analysed its inter-
action with b-catenin in the context of a truncated APC mol-
ecule containing inactivated 15R and 20R1. We found that the
20R2 cannot bind to b-catenin. Similarly, we also revealed
that the remaining piece of the 20R3 that is retained in
many truncated APC molecules is unable to interact efficiently
with b-catenin, indicating that mutations are selected for
altered b-catenin binding to the 20R3. Thus, our results
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strongly suggest that the conditions for a successful selection
of an APC mutation rely on keeping one single functional
20R, the 20R1, and therefore provide a functional definition
of the MCR in colorectal tumours.
The lack of b-catenin binding activity of the 20R2 was
investigated not only in co-immunoprecipitation experiments
in HEK293T (human embryonic kidney 293T) cells, but also
directly inside the cells in co-localization experiments in
SW480 cells. Despite their high expression levels relative
to endogenous APC in SW480 cells (unpublished data),
b-catenin was always localizing independently of the
exogenous APC constructs containing mutated 15R and
20R1 but wild-type 20R2. Thus our data provide the in
vivo confirmation that the 20R2 cannot bind to b-catenin.
They complement the previous in vitro observations that
highlighted the very weak affinity of the 20R2 towards
b-catenin when it was analysed individually using isother-
mal titration calorimetry, outside the APC context (35).
They also provide an explanation for the presence of a
lysine residue at position 1370 in the 20R2 instead of an
acidic residue directly interacting with b-catenin in the
20R1 and the 20R3 (31,32,34).
The b-catenin binding activity of the 20R3 was first inves-
tigated in co-immunoprecipitation experiments in HEK293T
cell extracts. A construct extending up to position 1519 in a
15R- and 20R1-mutated background (yAPC1519-15Rm-
20R1m) was binding efficiently to b-catenin. In contrast, the
deletion of residues 1503–1519 from this construct (as in
yAPC1502-15Rm-20R1m) abolished the interaction with
b-catenin (Fig. 5B). This result was obtained in an immuno-
precipitation experiment where the analysed components are
diluted upon addition of the cell-lysis buffer and immunopre-
cipitates extensively washed. This drives the equilibrium of
the interaction towards the dissociation. In contrast, in
co-localization experiments in MCF7 cells, the construct
yAPC1502-15Rm-20R1m was retaining b-catenin in the cyto-
plasm. We interpret this observation as the consequence of the
interaction of RFP-b-catenin with the remaining N-terminal
half of the 20R3. The C-terminal half of the 20R3 contains
several serine residues at positions (S1501, S1503, S1504,
S1505, S1507 and S1510) and their phosphorylation enhances
the affinity of the repeat for b-catenin (31,32). However, an in
vitro analysis performed with individual repeats revealed that
even in an unphosphorylated state, 20R3 displays an affinity
towards b-catenin comparable with a phosphorylated 20R1
(35). Our data indicated indeed that a 20R3 lacking five
known phosphorylatable serine residues (yAPC1502-15Rm-
20R1m) could still efficiently recruit b-catenin inside the
cells under the conditions of ectopic expression, likely
because the concentrations of the components were suffi-
ciently high to compensate for the decrease of affinity result-
ing from the deletion of the C-terminal half of the 20R3.
We pursued our deletion analysis to establish the limit under
which b-catenin recruitment would not be detectable anymore.
We found that the removal of E1494 (yAPC1493-15Rm-
20R1m) acted almost as a digital switch, sufficient to affect
seriously the recruitment of RFP-b-catenin, whereas the con-
struct containing this residue (yAPC1494-15Rm-20R1m) was
fully competent to interact with b-catenin. The crystallo-
graphic structure of a 20R3 in a complex with b-catenin
(31,32) indicates that D1486 and E1494 are two negatively
charged residues that form salt bridges with the two so-called
positively charged buttons of b-catenin in a crucial manner
(31,32,34). Thus, under conditions of ectopic expression, a
strong reduction of b-catenin recruitment to the 20R3 requires
the removal of E1494 in addition to the deletion of the phos-
phorylatable residues. The residual activity could be abolished
by further deletion of the remaining N-terminal half of the
20R3, which is also known to interact with b-catenin, particu-
larly the region located between the two important negatively
charged residues (31,32). Strikingly, the E1494 limit coincides
with the position where many recorded natural mutations
accumulate (Fig. 1). A few positions occurring after the criti-
cal E1494 position are however tolerated during tumour pro-
gression. We showed that the 20R3 as found in the context
of molecules extending up to positions 1502 or 1519 and
reproducing the situations in tumour samples (21) recruit
b-catenin less efficiently than a shorter construct extending
up to amino acid 1494 despite conditions of over-expression.
This suggests that the few truncated APC that are selected fol-
lowing a mutational hit occurring after position 1494 display a
20R3 with an altered b-catenin-binding activity, even if the
phosphorylatable residues are present as in yAPC1519-
15Rm-20R1m. This situation is however rarely observed,
likely because b-catenin binding is less affected in comparison
with truncations occurring before position 1494. An effective
selection might require in addition the reduction of the APC
level, as we observed it in HT29 cells containing a truncating
mutation at position 1555 and expressing lower amounts of
APC than SW480, DLD1 and LoVo colon cancer cells
where APC is truncated before position 1494 (unpublished
data). Alternatively, other proteins affecting the interaction
with the third repeat may contribute to the selection.
A nuclear export signal (NES) located within the phosphor-
ylatable region of the 20R3 between positions 1505 and 1512
has been previously described (43). According to this work,
APC truncations would be selected for the lack of this NES,
implying an altered ability to export b-catenin from the
nucleus. Whatever the outcome of the current discussion
about the nuclear localization of APC is (44), there is still a
gap between the core sequence of the putative NES and the
accumulation of mutations at position 1494, suggesting that
an additional factor is involved in the selection. Our data
strongly support the notion that truncated APC are selected
for impaired b-catenin binding to the 20R3, in addition to
the removal of the axin/conductin binding sites and the
NES. We propose that E1494 represents the 30 border of the
MCR and that mutations selected after this position are excep-
tions whose phenotype is expressed in an analogous way.
Truncated APC molecules selected in colon cancer retain
almost systematically a functional 20R1, although some rare
exceptions must be also highlighted (Fig. 1). As we have
shown here that the 20R2 cannot bind to b-catenin and that
the 20R3 is inactivated, this drives to the conclusion that trun-
cated APC are selected for the presence of a single functional
20R. The selection itself shows that some b-catenin binding
activity must be kept and that it is crucial for the tumour
cell. Actually, the presence of truncated APC seems essential
for optimal cell proliferation (28). At the molecular level, the
reason for the selection is not yet clear. Several studies have
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highlighted the potential of truncated APC to downregulate the
transcriptional activity of b-catenin (45–47) even without
affecting its stability (30), but the consequences in terms of
intracellular signalling remain unravelled. Nevertheless, the
present study strongly suggests that truncated APC are
selected for one common feature, an equivalent ability to
interact with b-catenin. It provides a functional definition of
the MCR.
MATERIALS AND METHODS
Materials
ProtA/G-sepharose was from Santa Cruz Biotechnologies
(Heidelberg, Germany) and Hoechst 33258 from Sigma
(Steinheim, Germany).
Cells
HEK293T, MCF7 and SW480 colon cancer cells were main-
tained in DMEM medium (PAA Laboratories, Co¨lbe,
Germany) supplemented with 10% fetal calf serum (Perbio
Laboratories, Frankfurt am Main, Germany) and 1% penicillin
and 1% streptomycin (PAA Laboratories).
Antibodies
Rabbit antibody H102 against b-catenin was purchased from
Santa Cruz. Secondary antibodies coupled to either horse-
radish peroxidase or Cy3 were from Dianova (Hamburg,
Germany), anti-b-actin from Santa Cruz Biotechnologies
(Heidelberg, Germany), and anti-GFP (green fluorescent
protein) from Roche (Mannheim, Germany).
Plasmids
Plasmids expressing the YFP-APC fusion proteins were con-
structed using standard molecular biology methods, using
pCMV-APC2843 (48) as a template for PCR (polymerase
chain reaction) reactions and YFP-APC (42) as a recipient
vector. The plasmid RFP-b-catenin was created using mRFP
(49) as a template for PCR and YFP-b-catenin (42) as the reci-
pient vector. The sequence of any of these plasmids is avail-
able upon request. The plasmid expressing myc-b-catenin
was described earlier (50).
Transfection
Plasmids were transfected into cells overnight using 5 ml poly-
ethylenimine (1 mg/ml) per mg DNA. For transient transfec-
tion of plasmids, 2 mg total DNA/200 000 cells/35 mm dish
were used. Expression was allowed to proceed for 24 h.
Cytosolic cell extracts
Cytosolic cell extracts were prepared as previously described
(51).
Western blotting
Western blotting was performed according to (11) The blots
were developed using the chemiluminescence reagents
Western LightningTM (Perkin Elmer Life Sciences, Boston,
MA, USA) and the signals were detected under a LAS-
3000-Fuji camera from Raytest (Straubenhardt, Germany).
Immunoprecipitations and immunofluorescence
Immunoprecipitations and immunofluorescence were con-
ducted as described (11).
TOP/FOP reporter assays
The TOPglow reporter consists of a tandem repeat of four
TCF/LEF1 binding sites inserted in front of a TATA box,
driving the expression of luciferase in a b-catenin-dependent
manner. In the FOPglow reporter, the four binding sites are
mutated to abolish the binding of TCF/LEF1. The internal
control pUHC16.1 encoding the b-galactosidase was transi-
ently transfected together with either FOP or TOP plasmids
at a ratio 1:1. The ratio of pUHC16.1 to any additional
plasmid was 1:2. The transcriptional activity measured 24 h
post-transfection is defined as the ratio of TOP and FOP luci-
ferase values normalized to the b-galactosidase values.
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